FDA Brief

Warning letters Drugs

FDA warning letter to

Matte Beauty

High riskIssued Jul 25, 2024Posted Jul 30, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Matte Beauty that its chemical peel drugs are unapproved and sold with treatment claims.

What happened

FDA reviewed Matte Beauty's website in March and April 2024 and its Instagram page and found chemical peels offered for sale in the U.S. with claims to treat acne, scars, wrinkles, pigmentation, and other skin conditions. FDA said these claims make the products drugs, and no FDA-approved application is in effect for them.

What FDA found

  1. Website and Instagram claims say the chemical peels treat acne, scars, wrinkles, pigmentation, and other conditions or affect skin structure, so FDA treats them as drugs.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The chemical peels are not generally recognized as safe and effective for those claimed uses, so they are new drugs under the law.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. No FDA-approved application is in effect for these products.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  4. The products were introduced or delivered for introduction into interstate commerce without an approved application.

    Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)

What FDA wants

FDA asks Matte Beauty to respond in writing within 15 working days of receipt, describing specific steps taken to correct the violations, how it will prevent recurrence, and related documentation; if it cannot finish within that time, it must give the reason and a completion date.

Who should pay attention

  • online sellers of at-home chemical peels
  • brands that market acids with medical claims
  • clinics and consumers buying peel products online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk